Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development. (4th May 2019)

• Record Type: Journal Article
• Authors: Dasari, Vijayendra; Sinha, Debottam; Neller, Michelle A.; Smith, Corey; Khanna, Rajiv
• Is Part Of: Expert review of vaccines. Volume 18:Number 5(2019)
• Page Start: 457
• Page End: 474
• Publication Date: 2019-05-04
• Subjects: Epstein–Barr virus -- prophylactic vaccines -- therapeutic vaccines -- immunotherapies -- infectious mononucleosis -- nasopharyngeal carcinoma -- post-transplant lymphoproliferative disorder; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2019.1605906
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction : Epstein–Barr virus (EBV) infects more than 95% of the world's population and is associated with infectious mononucleosis as well as a number of cancers in various geographical locations. Despite its significant health burden, no licenced prophylactic or therapeutic vaccines are available. Areas covered : Over the last two decades, our understanding of the role of EBV infection in the pathogenesis and immune regulation of EBV-associated diseases has provided new lines of research to conceptualize various novel prophylactic and therapeutic approaches to control EBV-associated disease. In this review, we evaluate the prophylactic and therapeutic vaccine approaches against EBV and various immunotherapeutic strategies against a number of EBV-associated malignancies. This review also describes the existing and future prospects of improved EBV-targeted therapeutic strategies. Expert opinion : It is anticipated that these emerging strategies will provide answers for the major challenges in EBV vaccine development and help improve the efficacy of novel therapeutic strategies.